GENinCode UK Ltd. (GENI) AI Stock Analysis

• Market Cap: £11.76M
• Dividend Yield: N/A
• Average Volume (3M): 1.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.50
• Revenue Growth: 25.05%
• EPS Growth: 65.30%
• Country: UK
• Employees: 42
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.01
• Shares Outstanding: 286,882,050
• 10 Day Avg. Volume: 2,331,567
• 30 Day Avg. Volume: 1,035,556
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £4.00
• Price Target Upside: -2.44% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 49 Neutral
• Price Target: 4.00p ▼(-2.44% Downside)

The overall stock score is primarily impacted by the company's financial performance, which is marked by persistent losses and cash flow challenges. Despite strong technical indicators suggesting positive momentum, the negative valuation metrics due to ongoing losses weigh heavily on the score. The lack of earnings call data and corporate events further limits the assessment.

GENinCode UK Ltd. Business Overview & Revenue Model

Company Description

GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.

How the Company Makes Money

GENinCode UK Ltd. generates revenue through the sale of its proprietary genetic testing services. The company's key revenue streams include direct sales of genetic tests to healthcare providers, clinics, and hospitals, as well as partnerships with medical institutions and research organizations. GENinCode may also generate income through collaborations with pharmaceutical companies seeking to integrate genetic risk assessments into clinical trials and drug development processes. Additionally, the company might engage in licensing agreements for its technology and intellectual property with other entities in the healthcare and biotechnology sectors.

GENinCode UK Ltd. Financial Statement Overview

Summary

GENinCode UK Ltd. is facing ongoing financial challenges, characterized by persistent losses and cash flow constraints. While revenue growth is a positive sign, the company's inability to achieve profitability, coupled with declining equity and reliance on external financing, highlights significant risks.

Income Statement

The income statement reveals persistent challenges, with a series of net losses despite a steady increase in revenue from 2020 to 2024. The gross profit margin has shown improvement, but the net profit margin remains negative due to significant operating losses as evidenced by negative EBIT and EBITDA margins. The company is working on expanding its revenue base; however, profitability remains a challenge.

Balance Sheet

The balance sheet shows a decline in stockholders' equity over the years, with a negative equity encountered in 2019. While the company has maintained low levels of debt, the equity ratio has decreased significantly, indicating financial vulnerability. The return on equity is negative, reflecting ongoing losses.

Cash Flow

Cash flow analysis points to significant negative operating cash flows, indicating challenges in generating cash from operations. Although there has been improvement in free cash flow over the recent period, the overall trend remains negative. The company relies heavily on financing activities to support operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.70M	2.16M	1.43M	1.15M	960.80K
Gross Profit	1.43M	1.02M	632.00K	593.00K	523.02K
EBITDA	-4.69M	-6.65M	-5.57M	-4.10M	-1.03M
Net Income	-4.43M	-7.02M	-5.56M	-4.14M	-1.07M
Balance Sheet
Total Assets	2.66M	4.19M	11.80M	15.21M	2.42M
Cash, Cash Equivalents and Short-Term Investments	1.17M	2.53M	9.75M	14.56M	2.00M
Total Debt	234.00K	299.00K	354.00K	0.00	0.00
Total Liabilities	1.54M	2.90M	3.90M	1.49M	563.50K
Stockholders Equity	1.13M	1.29M	7.90M	13.72M	1.86M
Cash Flow
Free Cash Flow	-5.22M	-7.54M	-4.61M	-3.17M	-1.11M
Operating Cash Flow	-5.17M	-7.51M	-3.76M	-3.02M	-1.04M
Investing Cash Flow	50.00K	136.00K	-849.00K	-145.00K	-68.27K
Financing Cash Flow	3.65M	-94.00K	-47.00K	15.86M	3.03M

GENinCode UK Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GENI, the sentiment is Positive. The current price of 4.1 is above the 20-day moving average (MA) of 1.78, above the 50-day MA of 1.75, and above the 200-day MA of 2.63, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 73.54 is Negative, neither overbought nor oversold. The STOCH value of 71.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GENI.

GENinCode UK Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABDX	59 Neutral	11.23M	-7.95	0.00%	―	27.60%	1.35%
GDR	51 Neutral	3.59M	-0.16	0.00%	―	125.37%	22.47%
GENI	49 Neutral	£11.76M	―	-367.05%	―	25.05%	65.30%
VRCI	44 Neutral	11.35M	-0.35	-111.57%	―	226.45%	53.51%
PRM	40 Underperform	10.21M	-2.61	52.27%	―	-2.80%	-38.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

GENinCode UK Ltd. Corporate Events

GENinCode Plc Observes Unexpected Share Price Movement Amid Ongoing FDA Discussions

GENinCode Plc has observed a sudden movement in its share price, which the company believes is not reflective of its current value. The company continues to progress in its FDA De Novo discussions and is working on collaborations for test distribution in the US and EU, with further updates expected at the interim results on 30 September 2025.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode to Release Interim Results and Host Investor Briefing

GENinCode Plc announced the release of its unaudited interim results for the first half of 2025, scheduled for September 30. The company will hold a briefing for equity research analysts and a live investor presentation on October 2, led by CEO Matthew Walls and CFO Paul Foulger. This announcement underscores GENinCode’s commitment to transparency and engagement with stakeholders, potentially enhancing its market positioning in the predictive genetics industry.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode Reports Revenue Growth and Advances Strategic Initiatives in H1 2025

GENinCode Plc reported a 15% increase in revenue to £1.6m for the first half of 2025, driven by growth in the UK, EU, and US markets. Despite maintaining a steady gross profit margin of 53%, the company faced losses of £2.4m. The company is progressing with FDA De Novo discussions and advancing collaboration talks for test distribution in the US and EU. New clinical data on their CARDIO inCode-Score was presented at major cardiology conferences, highlighting its significance in cholesterol risk modulation for coronary heart disease.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

GENinCode Updates on FDA De Novo Submission Progress

GENinCode Plc announced an update on its FDA De Novo submission, revealing that while the number of outstanding deficiencies has decreased, further information related to clinical validation is still required. The company remains optimistic about addressing these deficiencies through ongoing discussions with the FDA, although there is no certainty that the information provided will be sufficient for approval.

GENinCode Plc Successfully Passes All Resolutions at AGM

GENinCode Plc announced that all resolutions were passed at their Annual General Meeting held in Oxford, UK. This development underscores the company’s continued focus on advancing its predictive genetics technology in the prevention of cardiovascular disease and ovarian cancer, potentially strengthening its market position and stakeholder confidence.